There is a high incidence of severe acute and persistent cancer-related fatigue in survivors of Hodgkin lymphoma, regardless of tumor stage or treatment, according to a study published in The Lancet Oncology.1
Because there are limited data on the development of fatigue persisting years after treatment completion, researchers sought to evaluate fatigue in patients with early-stage favorable, early-stage unfavorable, and advanced-stage Hodgkin lymphoma who received first-line therapy.
Investigators analyzed data from the HD13, HD14, and HD15 trials, which included a total of 5306 patients. Of those, 4215 had valid fatigue assessment up to 5 years following the completion of therapy.
Fatigue was measured using the fatigue scale of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire, which patients completed at diagnosis, and 2 and 5 years after the end of treatment.
Results showed that patients with high tumor burden at the time of diagnosis had more fatigue at baseline. Cancer-related fatigue persisted in the second and fifth years after the end of treatment.
Baseline fatigue and age were each associated with fatigue in the second and fifth year after the end of treatment (both P <.0001). The study further revealed that patient sex and disease-specific risk factors at baseline did not significantly improve the prognosis of fatigue at any of the 3 assessment points.
In addition, treatment approach did not significantly impact fatigue scores in the second or fifth year after treatment.
1. Kreissl S, Mueller H, Goergen H, et al. Cancer-related fatigue in patients with and survivors of Hodgkin’s lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol. 2016 Sep 6. doi: 10.1016/S1470-2045(16)30093-6. [Epub ahead of print]